Literature DB >> 8111827

Cloning and expression of an anti-nerve growth factor (NGF) antibody for studies using the neuroantibody approach.

F Ruberti1, A Bradbury, A Cattaneo.   

Abstract

1. The neuroantibody approach, based on the expression of selected monoclonal antibodies by cells of the nervous system, has recently been described (Cattaneo and Neuberger, 1987; Piccioli et al., 1991). In order to apply this experimental strategy to study the role of nerve growth factor (NGF) in the central nervous system (CNS), we exploited the monoclonal antibody (mAb), alpha D11, which neutralizes very efficiently the biological activity of NGF, both in vitro and in vivo (Cattaneo et al., 1988). 2. The alpha D11 antibody chains were cloned and expressed in COS cells as rat/human chimaeric proteins. The cloned antibody was shown to display all the properties of the parental alpha D11 antibody, including its ability to neutralize NGF biological activity. 3. This will allow us to engineer the expression of recombinant alpha D11 antibodies in the CNS, to study the role of NGF in the developing and adult nervous system. This approach can be extended to other neurotrophic factors for which neutralizing monoclonal antibodies are available.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8111827     DOI: 10.1007/bf00711464

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  14 in total

1.  Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

Authors:  R Orlandi; D H Güssow; P T Jones; G Winter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  The nerve growth factor: purification as a 30,000-molecular-weight protein.

Authors:  V Bocchini; P U Angeletti
Journal:  Proc Natl Acad Sci U S A       Date:  1969-10       Impact factor: 11.205

3.  Second symposium on catecholamines. Modification of sympathetic function. Immunosympathectomy.

Authors:  R Levi-Montalcini; P U Angeletti
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

4.  Large scale purification and immunological characterization of human placental nerve growth factor.

Authors:  E Bigon; C Soranzo; C Minozzi; S D Skaper; L Callegaro
Journal:  Neurochem Res       Date:  1990-12       Impact factor: 3.996

Review 5.  The changing scene of neurotrophic factors.

Authors:  H Thoenen
Journal:  Trends Neurosci       Date:  1991-05       Impact factor: 13.837

6.  Expression and targeting of intracellular antibodies in mammalian cells.

Authors:  S Biocca; M S Neuberger; A Cattaneo
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

7.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

Authors:  L A Greene; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

8.  Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor.

Authors:  A Cattaneo; B Rapposelli; P Calissano
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

9.  Hidden receptors for nerve growth factor in PC12 cells.

Authors:  A Cattaneo; S Biocca; S Nasi; P Calissano
Journal:  Eur J Biochem       Date:  1983-09-15

10.  Polymeric immunoglobulin M is secreted by transfectants of non-lymphoid cells in the absence of immunoglobulin J chain.

Authors:  A Cattaneo; M S Neuberger
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  11 in total

Review 1.  On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease.

Authors:  Simona Capsoni; Antonino Cattaneo
Journal:  Cell Mol Neurobiol       Date:  2006-08-31       Impact factor: 5.046

2.  A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.

Authors:  David P Gearing; Elena R Virtue; Robert P Gearing; Alexander C Drew
Journal:  BMC Vet Res       Date:  2013-11-09       Impact factor: 2.741

3.  Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody.

Authors:  A Cattaneo; S Capsoni; E Margotti; M Righi; E Kontsekova; P Pavlik; P Filipcik; M Novak
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

4.  Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy.

Authors:  F Ruberti; S Capsoni; A Comparini; E Di Daniel; J Franzot; S Gonfloni; G Rossi; N Berardi; A Cattaneo
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

5.  Monoclonal antibodies to nerve growth factor affect the postnatal development of the visual system.

Authors:  N Berardi; A Cellerino; L Domenici; M Fagiolini; T Pizzorusso; A Cattaneo; L Maffei
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

Review 6.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction.

Authors:  Laura Lagostena; Marcelo Rosato-Siri; Mara D'Onofrio; Rossella Brandi; Ivan Arisi; Simona Capsoni; Jessica Franzot; Antonino Cattaneo; Enrico Cherubini
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

8.  Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.

Authors:  Sonia Covaceuszach; Sara Marinelli; Ivet Krastanova; Gabriele Ugolini; Flaminia Pavone; Doriano Lamba; Antonino Cattaneo
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

9.  In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.

Authors:  D P Gearing; M Huebner; E R Virtue; K Knight; P Hansen; B D X Lascelles; R P Gearing; A C Drew
Journal:  J Vet Intern Med       Date:  2016-06-15       Impact factor: 3.333

10.  Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration.

Authors:  Rodney R Walters; Joseph F Boucher; Flavia De Toni
Journal:  Front Vet Sci       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.